



## 2022 – 2023 ACTRIMS Didactic Series

### Disclosure Information

As a provider dedicated to independent education and accredited by the ACCME, IPMA must ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All individuals with potential to influence the content of this program have disclosed all financial relationships that have occurred in the past 24 months with ineligible companies. The disclosures have been reviewed according to policy and these declarations are listed below. All individuals with potential conflicts have been contacted as needed by IPMA staff, and issues of conflict have been discussed, managed, and mitigated.

Individual	Role	Disclosure
Daniel Alejandro Crespo Artunduaga, MD	Planner	No relevant relationships with ineligible companies to disclose
Brenda Banwell, MD	Faculty	<i>Consultant:</i> Novartis, UCB, Roche, Sanofi
Joseph Berger, MD	Faculty	<i>Consultant:</i> Celgene/BMS, Cellevolve, EMD Serono/Merck, Genentech, Genzyme, Janssen/J&J, Morphic, NeuVIR, Novartis, Roche
Riley Bove, MD	Faculty	<i>Advisory Board, Consultant &amp; Research:</i> Novartis <i>Advisory Board &amp; Research:</i> Biogen <i>Research:</i> EMD Serono <i>Advisory Board:</i> Alexion, TG Therapeutics <i>Advisory Board &amp; Consultant:</i> Genzyme Sanofi
Daniel Chapman, MD	Planner	No relevant relationships with ineligible companies to disclose
Daniel Alejandro Crespo Artunduaga, MD	Planner	No relevant relationships with ineligible companies to disclose
Nina S. Davis, MD	Faculty	No relevant relationships with ineligible companies to disclose
Eoin Flanagan, MBBCh	Faculty	<i>Advisory Board:</i> Alexion, Genentech, Horizon Therapeutics, UCB
Jeffrey Gelfand, MD	Faculty	<i>Consultant:</i> Biogen, Alexion; <i>Research:</i> Roche/Genentech, Vigil Neurosciences; <i>Trial Steering Committee:</i> OBOE (ocrelizumab, MS) and CIELO (satralizumab, AE) clinical trials
Sarah Hopkins, MD	Planner	No relevant relationships with ineligible companies to disclose
Le Hua, MD	Planner	<i>Advisory Board, Consultant &amp; Research:</i> EMD Serono, Novartis <i>Consultant &amp; Research:</i> Genentech <i>Consultant:</i> Genzyme <i>Consultant, Research, Speakers Bureau:</i> Bristol Myers Squibb <i>Research:</i> Biogen <i>Consultant:</i> Horizon Therapeutics, Alexion, Greenwich Biosciences
Mirhir Kakara, MD	Planner	No relevant relationships with ineligible companies to disclose
Ariel Lefland, MD	Planner	No relevant relationships with ineligible companies to disclose
Erin Longbrake, MD, PhD	Faculty	<i>Consultant &amp; Research:</i> Genentech <i>Consultant:</i> Bristol Myers Squibb, Biogen, Janssen, NGM Bio, TG Therapeutics
Christopher Luzzio, MD	Content Review	No relevant relationships with ineligible companies to disclose
Wendy Macklin, PhD	Faculty	No relevant relationships with ineligible companies to disclose
Andrew McKeon, MD	Faculty	<i>Consultant:</i> Janssen, Roche; <i>Research:</i> Euroimmun, AG; <i>Royalties:</i> Septin & MAP1B Abs; <i>Patents:</i> MAP1B, GFAP, Septin-5/7 Abs
Heidi Ness	Planner	No relevant relationships with ineligible companies to disclose
Ahmed Obeidat, MD	Planner	<i>Advisory Board, Consultant, Speakers Bureau:</i> Alexion Pharmaceuticals, Biogen, Bristol Myers Squibb, Genentech <i>Horizon Therapeutics Advisory Board, Consultant, Research:</i>

		Celgene, GW Pharma/Jazz Pharma, Sanofi/Genzyme, Novartis TG Therapeutics <i>Advisory Board, Consultant, Research,</i> <i>Speakers Bureau:</i> EMD Serono <i>Research:</i> Atara Biotherapeutics
Bruce Trapp, MD	Faculty	No relevant relationships with ineligible companies to disclose
Emily Viles-Monari	Planner	No relevant relationships with ineligible companies to disclose
Andrew Wolf, MD	Planner	No relevant relationships with ineligible companies to disclose
Vijayshree Yadav, MD	Planner	No relevant relationships with ineligible companies to disclose